Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Other(2)

Detailed Status

unknown2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

NCT05770180
unknownphase_1

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

NCT05552573
unknownphase_2

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

NCT05033847

Clinical Trials (3)

Showing 3 of 3 trials
NCT05770180Phase 2

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

Completed
NCT05552573Phase 1

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

Unknown
NCT05033847Phase 2

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

Unknown

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3